Table 2 summarizes key studies done employing using various liposomal formulations
Overall, when administering GLP-1RA plus SGLT2i combination therapy, it is important to adopt an individualized approach to therapy taking into account individual preferences, costs and coverage, AE profile, consideration of kidney function and glucose-lowering efficacy, desire for weight loss, and comorbidities such as frailty [6, 22, 24]
SURPASS-4 Investigators
When clinically appropriate, GLP-1 therapy can help lower cardiometabolic strain and inflammatory burden while complementing, not replacing, lifestyle fundamentals such as nutrient-dense eating, regular movement, resistance training, adequate protein intake, and restorative sleep
We found that oligomeric DOCA-G1As strongly bind to ASBT, resulting in the formation of ASBT vesicles through ASBT-mediated endocytosis